The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ Bcell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo. |